TRVI - CIK 0001563880
Trevi Therapeutics, Inc. trades as TRVI and has a market capitalization of $1.90 B, making it the #2129 largest US-listed company by market value. This page tracks Trevi Therapeutics, Inc. through 524 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13D/A | - | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Proxy statement | DEF 14A | 2026-04-21 |
| Annual report to shareholders | ARS | 2026-04-21 |
| Proxy materials | DEFA14A | 2026-04-21 |
| Prospectus supplement | 424B5 | 2026-04-17 |
The largest companies sharing Trevi Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Trevi Therapeutics, Inc. (TRVI) has a market capitalization of $1.90 B as of 2026-06-10, ranking #2129 among US-listed companies.
In its latest fiscal year Trevi Therapeutics, Inc. reported a net loss of $42.76M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.